Top 3 Genomics Stocks to Consider for Your Portfolio
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.75 per share a year ago.
Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?
Gene editing seems like a great idea: Instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as Crispr. I previously covered two companies, Crispr Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a Crispr licensee. But it failed twice, with treatments aimed at eye disease and sickle cell disease/beta thalassemia. And its stock suffered badly.
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas Medicine, Inc. - Special Call
Editas Medicine, Inc. - Special Call Company Participants Gilmore O'Neill - President, CEO & Director Linda Burkly - Executive VP & Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Semenkow - Citigroup Inc., Research Division Alec Stranahan - BofA Securities, Research Division Mehdi Goudarzi - Truist Securities, Inc., Research Division Philip Nadeau - TD Cowen, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Huidong Wang - Barclays Bank PLC, Research Division Presentation Operator Good morning, everyone, and thank you for joining Editas Medicine webinar to unveil our lead development candidate, EDIT-401.
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.82 per share a year ago.
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
An updated edition of the June 27, 2025, article.
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) BofA Securities 2025 Healthcare Conference May 14, 2025 8:15 PM ET Company Participants Amy Parison - CFO Christi Bernett - SVP of IR Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Welcome to the last fireside for day 1 of the 2025 Bank of America Healthcare Conference. Thanks for joining this session with Editas.
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
